To report potential adverse events to regulators like the EMA and FDA, drug manufacturers need to expand how they gather data. Relying on social media posts, call centers, CRMs, and other channels can create an ecosystem of unstructured data that is overwhelmingly complex and broad. The solution? Artificial intelligence (AI) and natural language processing (NLP).

In this infographic, learn more about how pharma companies are leveraging AI and NLP to collect data on adverse events and why many are turning to IQVIA’s Vigilance Detect — which combines the potential of AI and NLP with a GxP compliant workflow for multiple real-life applications across pharmacovigilance.

Read now to learn more about:

• The potential of AI and NLP
• 3 applications of Vigilance Detect
• Drug safety surveillance, by the numbers

​